StockData

Elutia vs Scilex

ELUT and SCLX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ELUT and SCLX compare

Elutia is the larger company, worth 3.6 times as much as Scilex ($37.8M against $10.6M).

Elutia grew revenue faster over the last twelve months (−0.34% versus −28.5% for Scilex).

Elutia keeps more of each dollar of sales as profit, with a net margin of 427% compared with −1470% at Scilex.

Elutia scores higher on the StockData Score (9 against 1 for Scilex), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricELUTSCLX
Size and price
Market cap$37.8M$10.6M
Share price$0.854$1.25
Change, 1 year14.5%−93.0%
Change, 5 years−83.6%−99.6%
Beta (5Y)0.372.18
Employees2634
StockData Score
Total score9 (better)1
Valuation score11
Growth score1 (better)0
Performance score2 (better)0
Health score5 (better)0
Dividend score00
Valuation
P/S3.1×0.3× (better)
P/B2.4×–
FCF yield−122%–
Fair value$0.913–
Margin of safety6.5%–
Growth
Revenue growth (TTM)−0.34% (better)−28.5%
Revenue growth, 5Y average−22.0%5.1% (better)
Profitability
Gross margin57.8%161% (better)
Operating margin−215% (better)−1136%
Net margin427% (better)−1470%
FCF margin−379%–
Financial health
Debt / equity0.00–
Interest coverage–−22.2×
Current ratio1.77 (better)0.07
Altman Z-score−6.57 (better)−12.75
Piotroski F-score6 (better)4
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions39.8%9.8%
Held by insiders52.0%–
Insider net buying, 12 months$212K (better)−$12.8M
Short interest, % of float0.16%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.